Shanghai FTZ Fund invests in the innovative medicine CRO leading enterprise Tigermed
2020-08-12
Recently, Shanghai FTZ Fund has made an investment in Tigermed, a leading domestic innovative drug CRO enterprise. Tigermed provides pre-clinical, I-IV phase clinical trials, data management and biological statistics, registration and declaration and other whole process services for pharmaceutical product R&D.